Advertisement

Topics

Latest Biotechnology Products NewsRSS

08:54 EDT 30th May 2017 | BioPortfolio

West to Present on Biologics Trends at InnoPack Pharma Confex

EXTON, Pa., May 30, 2017 /PRNewswire/ -- (Booth #B-3) -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will deliver a presentation on best practices for improving patient outcomes through integrated containment and delivery systems on June 1, 2017 at the 6th Annual InnoPack Pharma Confex in M...

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th

PALO ALTO, Calif., May 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the Jefferies 2017 Global Healthcare Conference at 11:00 am ET on Wednesday, June 7, 2017, i...

Navidea Biopharmaceuticals Inc NAVB Financial and Strategic SWOT Analysis Review [Updated: 23052017] Prices from USD $125

Navidea Biopharmaceuticals Inc NAVB Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies tha...

Northwest Biotherapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Updated: 03052017] Prices from USD $350

Northwest Biotherapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Northwest Biotherapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership trans...

Keryx Biopharmaceuticals Inc KERX Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 12052017] Prices from USD $250

SummaryKeryx Biopharmaceuticals Inc Keryx develops and commercializes new therapies for the treatment of renal disease. The company's lead product Auryxia ferric citrate is an FDA approved oral, absorbable ironbased phosphate binder, which helps lower the amount of phosphate in human blood. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This ...

Protalix BioTherapeutics Inc PLX Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 12052017] Prices from USD $250

SummaryProtalix BioTherapeutics Inc Protalix is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company's pipeline products include PRX102, a therapeutic enzyme for the treatment of Fabry disease; PRX110, a plant cellexpressed recombinant form of human deoxyribonuclease I and is intended for the treatment of cystic fibrosis. Its PRX106 is an orall...

Eleven Biotherapeutics reports $6.1 million loss in first quarter

Eleven Biotherapeutics reported a net loss of $6.1 million, or $0.25 per share, in the first quarter of 2017 compared with a net loss of $7.6 million, or $0.39 per share, in the same period of 2016. The company had revenues of $0.4 million in the first quarter compared with $0.2 million last year, according to a press release.

RegeneRx Biopharmaceuticals Inc RGRX Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 12052017] Prices from USD $250

SummaryRegeneRx Biopharmaceuticals Inc RegeneRx is a biotechnology company that offers clinical stage drug development solutions. The company offers clinical trials, science and discovery and business development services. Its business development services include clinical development and commercialization interests in desired pharmaceutical therapeutic fields for suitable infrastructure, expertis...

Top Three Global Diagnostics Company takes Exclusive Rights to Several of Avacta’s Affimer Reagents

Important value inflection point validating commercial potential of Affimer technology and Company's business model Avacta Group plc, the developer of Affimer® biotherapeutics and research reagents, is pleased to report that an evaluation of the Affimer technology by a large, global diagnostics developer has concluded successfully and that the third party has taken exclusive rights to sev...

EMA approval for insulin and rituximab biosimilars

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 19 May 2017 that it had recommended granting marketing authorization for Insulin lispro Sanofi and for the rituximab biosimilars Blitzima, Ritemvia and Tuxella.

Biosimilar substitution in Europe

In the European Union (EU), decisions on the interchangeability or substitution of biosimilars and originator biologicals are not made by the European Medicines Agency (EMA), but at the national level. This is despite the fact that biosimilars developed in line with EU requirements are considered by EMA to be therapeutic alternatives to their reference biologicals.

Lawmakers urge CMS to reverse its biosimilars policy

Senator Pat Roberts and Representatives Joe Barton and Anna Eshoo, along with a delegation of 52 House Members and nine Senators, have asked the Centers for Medicare & Medicaid Services (CMS) to reverse its biosimilars policy.

Biosimilars in the treatment of inflammatory bowel disease

Inflammatory bowel disease (IBD) is mainly characterized by two chronic, relapsing, immune-mediated inflammatory diseases of the gastrointestinal tract: Crohn’s disease and ulcerative colitis. Approximately 1.4 million Americans are affected by IBD and afflicted with recurrent symptoms of bloody diarrhoea, abdominal pain, bowel obstruction, and other co-morbid conditions. The introduction of bio...

Generics and biosimilars: status in the EU

According to Medicines for Europe, without generic medicines Europe would have paid Euros 100 billion more for its medicines in 2014 alone. In a recent interview, the Association’s President Jacek Glinka spoke about the central issues surrounding the affordability and accessibility of medicines in the region.

Cipla Follows Merck KGaA's Footsteps, Drops Out of Biosimilars Biz

  Life Sciences Jobs   ...

FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications

Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company’s proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by a U.S...

Provenance Biopharmaceuticals Corp Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 12052017] Prices from USD $250

SummaryProvenance Biopharmaceuticals Corp Provenance is a biotechnology company that develops various novel immunotherapeutic drugs to treat cancer and other serious, lifethreatening diseases. The company offers cancer drugs based on antibodies which include avastin, erbitux, hercepton, and rituxan. Its DILeu16IL2 is an antibodycytokine fusion protein targeting the B cell antigen, CD20. The compan...

Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference

CARMIEL, Israel, May 25, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, wi...

Vaxil BioTherapeutics Launches Manufacturing Of Immucin Immunotherapy For Upcoming Clinical Trials

  Life Sciences Jobs   ...

Pierre Fabre Acquires Igenica Immuno-Oncology Assets

Pierre Fabre said today it has agreed to acquire “several” cancer immunotherapies from Igenica Biotherapeutics for an undisclosed price, in a deal designed to strengthen the buyer’s oncology pipeline. Pierre Fabre also did not disclose how many immuno-oncology candidates it acquired—but did say the most advanced of those is a preclinical asset “expected to be administered to patients...

EMA to review marketing authorization application of biosimilar to candidate to Humira

The European Medicines Agency has accepted to review the marketing authorization application for the adalimumab biosimilar candidate FKB327 for the treatment of patients with rheumatoid arthritis, according to a company press release.“We are delighted that [Europpean Medicines Agency] EMA has accepted this application,” Hideaki Nomura, president and chief executive officer of Fujifilm Kyowa Ki...

Pierre Fabre Acquires Ingenica Immuno-Oncology Assets

Pierre Fabre said today it has agreed to acquire “several” cancer immunotherapies from Igenica Biotherapeutics for an undisclosed price, in a deal designed to strengthen the buyer’s oncology pipeline. Pierre Fabre also did not disclose how many immuno-oncology candidates it acquired—but did say the most advanced of those is a preclinical asset “expected to be administered to patients...

Pierre Fabre Pharmaceuticals Acquires Promising Assets from Igenica Biotherapeutics in the Field of Immuno-Oncology

* In line with its open innovation strategy, this deal reinforces Pierre Fabre Pharmaceuticals’ pipeline in oncology, its primary R&D focus area *Pierre Fabre Pharmaceuticals will leverage its cutting-edge expertise in monoclonal antibodies and immuno-conjugates along with its capabilities in clinical development and translational medicine t...

Atara Biotherapeutics to Present at Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the Company will present at three upcoming investor conferences in June: Jefferies 2017 Global Healthcare Conference Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will present a corporate overview on Tuesday, June 6, 2017 at 3:30 p.m. E...

Bay Area's Asterias Biotherapeutics CEO to Step Down, New Leader Named

  Life Sciences Jobs   ...

Quick Search
Advertisement
 

review and buy Biotechnology Products market research data and corporate reports here